ZMapp is a drug, still experimental, developed to try to cure Ebola . It is a serum made up of three monoclonal antibodies that specifically bind to proteins present on the surface of the virus.
In practice, the patient is provided with a pre-packaged immune response: ZMapp prevents the virus from overcoming the cell membranes, then blocks it before it can multiply.
So far, the drug has been administered only in special cases, considering that its effectiveness is yet to be proven.
